Literature DB >> 31235143

Elevated fasting insulin is associated with cardiovascular and metabolic risk in women with polycystic ovary syndrome.

Shayaq Ul Abeer Rasool1, Sairish Ashraf2, Mudasar Nabi3, Fouzia Rashid4, Khalid Majid Fazili5, Shajrul Amin6.   

Abstract

AIMS: PCOS is associated with various immediate and long term health complications. The aim of this study was to investigate the association of serum fasting insulin concentration with cardiovascular and metabolic risk factors in women with polycystic ovary syndrome.
METHODS: A total of 349 women, 249 women with polycystic ovary syndrome and 100 age-matched healthy controls, were recruited in this case-control study. Fasting insulin and various other biochemical, hormonal and clinical parameters were measured in all participants. The correlation of insulin with cardiometabolic risk factors was evaluated in PCOS women with normal and high serum insulin concentration.
RESULTS: Fasting Insulin, BMI, WHR, FAI, LH: FSH, HOMA, QUICKI were significantly higher in PCOS women compared with healthy controls (p < 0.01). Fasting insulin showed a positive correlation with more cardiovascular and metabolic risk factors in PCOS compared to controls. The BMI, BAI, LAP, HOMA IR, QUICKI and FAI were significantly higher (all p < 0.05) in PCOS patients with higher insulin levels than with PCOS women with normal levels.
CONCLUSION: Fasting insulin is an important determinant in the pathogenesis of obesity and hyperandrogenism in PCOS. It is associated with an increased risk of cardiovascular and metabolic disorders in women with PCOS.
Copyright © 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hirsutism; Hyperandrogenism; Insulin; Insulin resistance; Menstrual dysfunction; Obesity; Polycystic ovary syndrome

Year:  2019        PMID: 31235143     DOI: 10.1016/j.dsx.2019.05.003

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  5 in total

1.  Integrated bioinformatics analysis and screening of hub genes in polycystic ovary syndrome.

Authors:  Gan Qiao; Jinshan Xing; Xin Luo; Chunxiang Zhang; Jingyan Yi
Journal:  Endocrine       Date:  2022-09-06       Impact factor: 3.925

2.  Long non-coding RNA HLA-F antisense RNA 1 inhibits the maturation of microRNA-613 in polycystic ovary syndrome to promote ovarian granulosa cell proliferation and inhibit cell apoptosis.

Authors:  Xiaohua Li; Laifang Zhu; Yan Luo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

3.  Quantitative Changes in White Blood Cells: Correlation with the Hallmarks of Polycystic Ovary Syndrome.

Authors:  Abdulrahman H Almaeen; Abdulrahman Abdulwahab Alduraywish; Mudasar Nabi; Naveed Nazir Shah; Rahiman Shaik; Bilal Ahmad Tantry
Journal:  Medicina (Kaunas)       Date:  2022-04-12       Impact factor: 2.948

4.  Clinical Manifestations of Hyperandrogenism and Ovulatory Dysfunction Are Not Associated with His1058 C/T SNP (rs1799817) Polymorphism of Insulin Receptor Gene Tyrosine Kinase Domain in Kashmiri Women with PCOS.

Authors:  Shayaq Ul Abeer Rasool; Sairish Ashraf; Mudasar Nabi; Shariq R Masoodi; Khalid M Fazili; Shajrul Amin
Journal:  Int J Endocrinol       Date:  2021-12-06       Impact factor: 3.257

5.  Insulin Receptor Substrate 1 Gly972Arg (rs1801278) Polymorphism Is Associated with Obesity and Insulin Resistance in Kashmiri Women with Polycystic Ovary Syndrome.

Authors:  Shayaq Ul Abeer Rasool; Mudasar Nabi; Sairish Ashraf; Shajrul Amin
Journal:  Genes (Basel)       Date:  2022-08-17       Impact factor: 4.141

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.